Trials / Completed
CompletedNCT01005901
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,324 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glycopyrronium bromide | Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI) |
| DRUG | Placebo | Placebo inhalation capsules were provided for use via a SDDPI |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-11-02
- Last updated
- 2012-04-12
- Results posted
- 2012-04-12
Locations
96 sites across 11 countries: United States, Australia, Canada, Japan, Netherlands, Romania, Russia, Singapore, South Korea, Spain, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01005901. Inclusion in this directory is not an endorsement.